Vera Therapeutics (NASDAQ:VERA – Get Free Report) and Newron Pharmaceuticals (OTCMKTS:NWPHF – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.
Volatility and Risk
Vera Therapeutics has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Comparatively, Newron Pharmaceuticals has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.
Institutional and Insider Ownership
99.2% of Vera Therapeutics shares are held by institutional investors. 21.7% of Vera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Ratings
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Vera Therapeutics | 0 | 1 | 6 | 1 | 3.00 |
Newron Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Vera Therapeutics presently has a consensus target price of $42.86, indicating a potential upside of 19.68%. Given Vera Therapeutics’ higher probable upside, equities research analysts clearly believe Vera Therapeutics is more favorable than Newron Pharmaceuticals.
Earnings and Valuation
This table compares Vera Therapeutics and Newron Pharmaceuticals’ revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Vera Therapeutics | N/A | N/A | -$95.99 million | ($2.05) | -17.42 |
Newron Pharmaceuticals | $6.82 million | 23.82 | -$17.63 million | N/A | N/A |
Newron Pharmaceuticals has higher revenue and earnings than Vera Therapeutics.
Profitability
This table compares Vera Therapeutics and Newron Pharmaceuticals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Vera Therapeutics | N/A | -52.43% | -39.06% |
Newron Pharmaceuticals | N/A | N/A | N/A |
Summary
Vera Therapeutics beats Newron Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
About Vera Therapeutics
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
About Newron Pharmaceuticals
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.